GSK to overtake Sanofi atop meningococcal vaccine market, report predicts


The meningococcal vaccine market is set for a shakeup as GlaxoSmithKline ($GSK)--on the heels of recent acquisitions and a launch--is expected to overtake Sanofi ($SNY) for the top spot in the coming years.

That’s according to a new report from GlobalData, which predicts Bexsero sales will swell to $570 million by 2025, helping propel the U.K. pharma past Sanofi and its Menactra. Also helping GSK, the report says, is the anticipated launch of a novel pentavalent MenABCWY jab, expected to debut in Europe and the U.S. during the period.


The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

Overall, GlobalData’s analysts expect the meningococcal vaccine market to grow from $1.1 billion in 2015 to $1.8 billion in 2025, a 5.4% annual expansion. Driving that will be changes to national immunization programs and the launch of GSK’s MenABCWY, currently in Phase II.

But so far, GSK is riding its momentum with Bexsero and Menveo, which reeled in £115 million ($167 million) and £160 million ($232 million) respectively last year following the pharma’s multibillion-dollar asset swap with Novartis ($NVS). After completing the swap, GSK inked a deal with the U.K. government to incorporate the jab into the country’s national immunization schedule, allowing British infants to access the vaccine at two months, four months and 12 to 13 months.

Demand for the jab was so strong that earlier this year GSK had a temporary shortage of the shot at private NHS clinics in the U.K. that has since been resolved.

But Sanofi Pasteur’s Menactra dwarfed those figures last year, with its sales up 18.2% to €563 million ($639 million). Sanofi has an ACWY conjugate vaccine in Phase II.

Early conservative sales estimates had Pfizer's ($PFE) Trumenba, which like Bexsero also protects against MenB, hitting peak sales of about $225 million in 2019.

- read the report

Related Articles:
Sanofi CEO: Vaccines business 'continues to deliver'
Glaxo's Bexsero supply rebounds after demand for MenB jab outstrips supply
Pfizer beats out Novartis with FDA MenB nod


Suggested Articles

Contradicting analysts' observations, Novartis CEO dubbed Zolgensma “one of the most successful launches from an access standpoint in rare diseases.”

Leading Indian drugmakers Sun Pharma, Cipla, Aurobindo and Dr. Reddy's are all trying to expand their presences in China.

New Gilead CEO Daniel O’Day has already replaced some key leaders at the company, but he’s not stopping there with the executive overhaul.